SCHEMBL24069065

SCHEMBL24069065

O=S(=O)(NCCCN1CCC(c2ccccc2)CC1)c1ccc(-c2ccccc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR7 P34969 5/20 0.56
▸ MBTD1 Q05BQ5 1/20 0.52
▸ L3MBTL1 Q9Y468 1/20 0.52
▸ OPRM1 P35372 1/20 0.52
▸ OPRK1 P41145 1/20 0.52
▸ KDM1A O60341 1/20 0.51
▸ SIGMAR1 Q99720 2/20 0.50
▸ HTR1A P08908 1/20 0.50
▸ CARM1 Q86X55 1/20 0.50
▸ PRMT6 Q96LA8 1/20 0.50
▸ SFRP1 Q8N474 1/20 0.50
▸ BCHE P06276 1/20 0.49
▸ KMT2A Q03164 2/20 0.49
▸ MEN1 O00255 1/20 0.49
▸ TP53 P04637 1/20 0.49
▸ CYP1A2 P05177 1/20 0.49
▸ CYP3A4 P08684 1/20 0.49
▸ CYP2D6 P10635 1/20 0.49
▸ TSHR P16473 1/20 0.49
▸ CYP2C19 P33261 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25758479 0.93 KDM1A (0.58) HTR7OPRM1OPRK1KDM1ASIGMAR1
SCHEMBL25758563 0.85 HTR7 (0.69) HTR7HTR1APOLB
SCHEMBL24069429 0.84 SLC6A2 (0.63) HTR7SIGMAR1CARM1PRMT6KMT2A
SCHEMBL18502069 0.83 MBTD1 (0.55) HTR7MBTD1L3MBTL1SIGMAR1HTR1A
SCHEMBL29022575 0.81 HTR7 (0.57) HTR7MBTD1L3MBTL1SIGMAR1CARM1
SCHEMBL24069058 0.81 HTR7 (0.85) HTR7MBTD1L3MBTL1HTR1AKMT2A
SCHEMBL29022599 0.81 HTR1A (0.74) HTR7OPRM1HTR1AKMT2AMEN1
SCHEMBL29022586 0.81 HTR7 (0.69) HTR7MBTD1L3MBTL1SIGMAR1HTR1A
SCHEMBL25290527 0.81 SLC6A2 (0.59) HTR7SIGMAR1HTR1ACARM1PRMT6
SCHEMBL18502080 0.80 HTR1A (0.52) HTR7MBTD1L3MBTL1SIGMAR1HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212121-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS TRINEURO (KR) 2023-07-06 — — US disclosed
US-20230212121-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS TRINEURO (KR) 2023-07-06 — — US disclosed
WO-2021241875-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS 재단법인 대구경북첨단의료산업진흥재단 2021-12-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212121-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS SLC6A2, SLC6A3, SLC6A4 HTR7 79/4885MBTD1 1384/4885L3MBTL1 4546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback